<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0122397</article-id>
<article-id pub-id-type="publisher-id">PONE-D-14-46194</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Efficacy of Shugan Jianpi Zhixie Therapy for Diarrhea-Predominant Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials</article-title>
<alt-title alt-title-type="running-head">Meta-Analysis: Shugan Jianpi Zhixie Therapy for Treating IBS-D</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Xiao</surname>
<given-names>Ya</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Liu</surname>
<given-names>Yanyan</given-names>
</name>
<xref rid="aff003" ref-type="aff"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Huang</surname>
<given-names>Shaohui</given-names>
</name>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Sun</surname>
<given-names>Xiaomin</given-names>
</name>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Tang</surname>
<given-names>Yang</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Cheng</surname>
<given-names>Jingru</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wang</surname>
<given-names>Tian</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Fei</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kuang</surname>
<given-names>Yuxiang</given-names>
</name>
<xref rid="aff004" ref-type="aff"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Luo</surname>
<given-names>Ren</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Zhao</surname>
<given-names>Xiaoshan</given-names>
</name>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
<xref rid="cor001" ref-type="corresp">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, China</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Rheumatic diseases, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Digestive Department of Guangdong provincial hospital of TCM, Guangzhou, 510120, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Green</surname>
<given-names>John</given-names>
</name>
<role>Academic Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University Hospital Llandough, UNITED KINGDOM</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: XSZ. Performed the experiments: XMS YT JRC TW FL YXK. Analyzed the data: YX YYL SHH. Contributed reagents/materials/analysis tools: YX YYL SHH. Wrote the paper: XY YYL SHH XSZ. Study supervision: XSZ RL.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">zhaoxs0609@163.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>8</day>
<month>4</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<year>2015</year>
</pub-date>
<volume>10</volume>
<issue>4</issue>
<elocation-id>e0122397</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>10</month>
<year>2014</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>2</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-year>2015</copyright-year>
<copyright-holder>Xiao et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0122397" xlink:type="simple"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>Shugan Jianpi Zhixie therapy (SJZT) has been widely used to treat diarrhea-predominant irritable bowel syndrome (IBS-D), but the results are still controversial. A meta-analysis of randomized, double-blind, placebo-controlled trials was performed to assess the efficacy and tolerability of SJZT for IBS-D.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>The MEDLINE, EMBASE, Cochrane Library, the China National Knowledge Infrastructure database, the Chinese Biomedical Literature database and the Wanfang database were searched up to June 2014 with no language restrictions. Summary estimates, including 95% confidence intervals (CI), were calculated for global symptom improvement, abdominal pain improvement, and Symptom Severity Scale (BSS) score.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>Seven trials (N=954) were included. The overall risk of bias assessment was low. SJZT showed significant improvement for global symptom compared to placebo (RR 1.61; 95% CI 1.24, 2.10; <italic>P</italic> =0.0004; therapeutic gain = 33.0%; number needed to treat (NNT) = 3.0). SJZT was significantly more likely to reduce overall BSS score (SMD –0.67; 95% CI –0.94, –0.40; <italic>P</italic> &lt; 0.00001) and improve abdominal pain (RR 4.34; 95% CI 2.64, 7.14; <italic>P</italic> &lt; 0.00001) than placebo. The adverse events of SJZT were no different from those of placebo.</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>This meta-analysis suggests that SJZT is an effective and safe therapy option for patients with IBS-D. However, due to the high clinical heterogeneity and small sample size of the included trials, further standardized preparation, large-scale and rigorously designed trials are needed.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>This work was supported by the NSFC-Guangdong joint fund (Nos. U1132001), the National Science Foundation of China (Nos. 81173146, 81373707 and 81403447), the State Administration of Traditional Chinese Medicine (Nos. JDZX2012013), the Major State Basic Research Development Program of China (973 Program Nos. 2013CB531700), the Guangdong Provincial Department of Science and Technology and Guangdong Provincial Academy of Traditional Chinese Medicine joint fund (Nos. 2011B032200004 and 2012A032500004), the Guangdong Provincial Department of Science and Technology fund (Nos. 2011B031700018), China Postdoctoral Science Foundation(Nos. 2014M552187), and Administration of Traditional Chinese Medicine of Guangdong Province, China (Nos. 2012KT1145). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="3"/>
<page-count count="12"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability" xlink:type="simple">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Irritable bowel syndrome (IBS) is associated with symptoms of chronic abdominal pain, bloating and disturbed defecation in the absence of any demonstrable biochemical and anatomical abnormality [<xref rid="pone.0122397.ref001" ref-type="bibr">1</xref>]. About 5%-22% of general population is affected by IBS among various countries [<xref rid="pone.0122397.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0122397.ref003" ref-type="bibr">3</xref>]. IBS causes significant reductions in patients’ quality of life and daily activities and involves substantial healthcare costs [<xref rid="pone.0122397.ref004" ref-type="bibr">4</xref>–<xref rid="pone.0122397.ref006" ref-type="bibr">6</xref>].</p>
<p>Although great progress has been made in the understanding of irritable bowel syndrome, conventional treatment remains unsatisfied. A series of systematic reviews of published drug trials were performed by the American College of Gastroenterology Task Force [<xref rid="pone.0122397.ref007" ref-type="bibr">7</xref>]. The quality of evidence for certain antispasmodics was graded as poor, and for tricyclic antidepressants, selective serotonin reuptake inhibitors, non-absorbable antibiotics, and C-2 chloride channel activators as moderate [<xref rid="pone.0122397.ref007" ref-type="bibr">7</xref>]. The trials of 5HT3 antagonists and 5HT4 agonists were of good quality, but it was noteworthy that these drugs were associated with a potential risk of ischemic colitis and cardiovascular events respectively [<xref rid="pone.0122397.ref007" ref-type="bibr">7</xref>].</p>
<p>Due to chronicity and frequency of symptoms, many patients seek alternative treatments such as traditional Chinese medicine (TCM) [<xref rid="pone.0122397.ref008" ref-type="bibr">8</xref>–<xref rid="pone.0122397.ref010" ref-type="bibr">10</xref>]. TCM is characterized by syndrome differentiation. In this regard, “stagnation of liver energy and deficiency of spleen” is considered to be the basic pathogenic factor of diarrhea-predominant IBS (IBS-D) [<xref rid="pone.0122397.ref011" ref-type="bibr">11</xref>]. Relieving the suppressed liver and replenishing the spleen energy for anti-diarrhea (Chinese name in pinyin “Shugan Jianpi Zhixie”) is the most important therapy in the treatment of IBS-D [<xref rid="pone.0122397.ref012" ref-type="bibr">12</xref>]. <italic>Tong Xie Yao Fang</italic>, an ancient formula with function of Shugan Jianpi Zhixie, has been prescribed by TCM practitioners for a long time in the treatment of IBS-D [<xref rid="pone.0122397.ref013" ref-type="bibr">13</xref>]. There was a systematic review of <italic>Tong Xie Yao Fang</italic> for IBS reported in 2006 [<xref rid="pone.0122397.ref014" ref-type="bibr">14</xref>]. In the review, twelve studies were included, but none of them were double-blind, placebo-controlled trials. The authors concluded that no definitive conclusions could be drawn due to the poor quality of the primary trials. Recently, increasing numbers of well-designed trials assessing Shugan Jianpi Zhixie therapy (SJZT) for IBS have been published [<xref rid="pone.0122397.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0122397.ref015" ref-type="bibr">15</xref>–<xref rid="pone.0122397.ref021" ref-type="bibr">21</xref>]. However, the current state of evidence of SJZT for IBS-D has so far been unknown. Therefore, we conducted a meta-analysis of randomized, double-blind, placebo-controlled trials to determine whether SJZT is beneficial to patients with IBS-D.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec007">
<title>Search strategy</title>
<p>A literature search was carried out using Medline (1989 to June 2014), EMBASE (1947 to June 2014), Cochrane Library (1993 to June 2014), the China National Knowledge Infrastructure database (1979 to June 2014), the Chinese Biomedical Literature database (1990 to June 2014) and the Wanfang database (1982 to June 2014). The search terms used were (traditional Chinese medicine OR herbal medicine OR herbs OR herbal formula OR Chinese medicinal herb OR Shugan OR Jianpi OR Zhixie) AND (irritable bowel syndrome OR IBS) AND (randomized controlled trial AND (double-blind trial OR placebo-controlled trial)). No limit was placed on language. Manual searches of relevant studies supplemented the electronic searches.</p>
</sec>
<sec id="sec008">
<title>Study selection</title>
<p>Studies meeting the following criteria were included. (i) Patients were diagnosed with IBS-D. (ii) The study was performed as a randomized, double-blind, placebo-controlled, parallel-group trial that compared the efficacy of SJZT vs. placebo. (iii) Outcomes included at least one of the following: global symptom improvement, IBS Symptom Severity Scale (BSS) score and abdominal pain improvement. Global symptom improvement was recorded as primary outcome, and overall BSS score and abdominal pain improvement were recorded as secondary outcome measures.</p>
</sec>
<sec id="sec009">
<title>Data abstraction</title>
<p>Two researchers independently extracted data, including study design, randomization, diagnostic criteria for IBS-D, TCM criteria, sample size, dose and ingredients of each formula in the included studies, treatment duration, primary and secondary outcomes. Data were extracted as intention-to-treat analyses, in which drop-outs were assumed to be treatment failures, wherever trial reporting allowed this. Disagreements were resolved after discussion with other investigators. Assessment of methodological quality was conducted according to the Cochrane Collaboration tool.</p>
</sec>
<sec id="sec010">
<title>Data synthesis and analysis</title>
<p>Summary relative risk (RR) and 95% confidence intervals (CI) were reported for both global symptom improvement and abdominal pain improvement. Standardized mean difference (SMD) and 95% CI were reported for BSS scores. The χ<sup>2</sup> test and the inconsistency index statistic (<italic>I</italic><sup>2</sup>) for heterogeneity were conducted [<xref rid="pone.0122397.ref022" ref-type="bibr">22</xref>]. If substantial heterogeneity occurred (<italic>I</italic><sup>2</sup> &gt;50% or <italic>P</italic>&lt;0.05), a random effect model was used to calculate the pooled RR [<xref rid="pone.0122397.ref023" ref-type="bibr">23</xref>]. If there was no observed heterogeneity, the pooled RR was computed by using a fixed effect model. A sensitivity analysis was done to investigate potential sources of heterogeneity between studies through omitting one trial in turn. The number needed to treat (NNT) was calculated as the reciprocal of the therapeutic gain. Begg’s test was performed to evaluate publication bias [<xref rid="pone.0122397.ref024" ref-type="bibr">24</xref>]. Review Manager 5.1 and Stata 12.0 were used for analyses.</p>
<p>We calculated the optimal information size (OIS) to provide appropriate sample size for the meta-analysis [<xref rid="pone.0122397.ref025" ref-type="bibr">25</xref>]. To determine the OIS, a 60% control event rate for the chance of not improving symptomatic was presumed for the outcome global symptom improvement and a 25% RR reduction with a power of 80% and a two-sided α value of 0.01[<xref rid="pone.0122397.ref026" ref-type="bibr">26</xref>].</p>
</sec>
</sec>
<sec id="sec011" sec-type="results">
<title>Results</title>
<p>A total of 85 relevant studies were identified by computer search. Of these, three articles were duplicates and 43 articles were excluded on review of abstracts. After further reviewing, seven studies (<italic>N</italic> = 954) satisfied the inclusion criteria for the meta-analysis (<xref rid="pone.0122397.g001" ref-type="fig">Fig 1</xref>). A description of the included trial characteristics can be found in <xref rid="pone.0122397.t001" ref-type="table">Table 1</xref>. The ingredients of herbal formulae were listed in <xref rid="pone.0122397.t002" ref-type="table">Table 2</xref>.</p>
<fig id="pone.0122397.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122397.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow chart of study selection process.</title>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122397.g001" position="float" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0122397.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122397.t001</object-id>
<label>Table 1</label> <caption><title>Characteristics of included studies.</title></caption>
<alternatives>
<graphic id="pone.0122397.t001g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122397.t001" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Author</th>
<th align="left" rowspan="1" colspan="1">Criteria</th>
<th align="left" rowspan="1" colspan="1">Study Population</th>
<th align="left" rowspan="1" colspan="1">TCM criteria</th>
<th align="left" rowspan="1" colspan="1">Primary outcome</th>
<th align="left" rowspan="1" colspan="1">Secondary outcomes</th>
<th align="left" rowspan="1" colspan="1"><italic>N</italic> (SJZT vs. placebo)</th>
<th align="left" rowspan="1" colspan="1">SJZT</th>
<th align="left" rowspan="1" colspan="1">Dose</th>
<th align="left" rowspan="1" colspan="1">Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Bensoussan et al. 1998 (15)</td>
<td align="left" rowspan="1" colspan="1">Rome I</td>
<td align="left" rowspan="1" colspan="1">Two centers</td>
<td align="left" rowspan="1" colspan="1">N.R</td>
<td align="left" rowspan="1" colspan="1">1. BSS score 2. Global symptom improvement</td>
<td align="left" rowspan="1" colspan="1">Interference with life</td>
<td align="left" rowspan="1" colspan="1">43 vs. 35</td>
<td align="left" rowspan="1" colspan="1">Standard formula</td>
<td align="left" rowspan="1" colspan="1">Five capsules, t.i.d.</td>
<td align="left" rowspan="1" colspan="1">16 weeks</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Leung et al. 2006 (12)</td>
<td align="left" rowspan="1" colspan="1">Rome II</td>
<td align="left" rowspan="1" colspan="1">Single center</td>
<td align="left" rowspan="1" colspan="1">stagnation of liver energy and deficiency of spleen</td>
<td align="left" rowspan="1" colspan="1">Global symptom improvement at 8 weeks</td>
<td align="left" rowspan="1" colspan="1">1. Global improvement at 4 weeks, 16 weeks 2. Individual symptom score 3. Daily bowel frequency 4. Bristol stool scales 5. Scales of the SF-36</td>
<td align="left" rowspan="1" colspan="1">60 vs. 59</td>
<td align="left" rowspan="1" colspan="1">Traditional Chinese herbal formula</td>
<td align="left" rowspan="1" colspan="1">One package, b.i.d.</td>
<td align="left" rowspan="1" colspan="1">8 weeks</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Li et al. 2010 (16)</td>
<td align="left" rowspan="1" colspan="1">RomeIII</td>
<td align="left" rowspan="1" colspan="1">Single center</td>
<td align="left" rowspan="1" colspan="1">stagnation of liver energy and deficiency of spleen</td>
<td align="left" rowspan="1" colspan="1">1. BSS score 2. Global symptom improvement</td>
<td align="left" rowspan="1" colspan="1">1. Daily bowel frequency 2. Abdominal pain improvement</td>
<td align="left" rowspan="1" colspan="1">30 vs. 30</td>
<td align="left" rowspan="1" colspan="1">Chang Ji Tai granule</td>
<td align="left" rowspan="1" colspan="1">One package, b.i.d.</td>
<td align="left" rowspan="1" colspan="1">4 weeks</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Chen et al. 2010 (17)</td>
<td align="left" rowspan="1" colspan="1">RomeIII</td>
<td align="left" rowspan="1" colspan="1">Multi-center</td>
<td align="left" rowspan="1" colspan="1">stagnation of liver energy and deficiency of spleen</td>
<td align="left" rowspan="1" colspan="1">Global symptom improvement</td>
<td align="left" rowspan="1" colspan="1">Abdominal pain improvement</td>
<td align="left" rowspan="1" colspan="1">329 vs. 113</td>
<td align="left" rowspan="1" colspan="1">Tong Xie Ning granule</td>
<td align="left" rowspan="1" colspan="1">5 g, t.i.d.</td>
<td align="left" rowspan="1" colspan="1">3 weeks</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Tang et al. 2011 (18)</td>
<td align="left" rowspan="1" colspan="1">RomeIII</td>
<td align="left" rowspan="1" colspan="1">Single center</td>
<td align="left" rowspan="1" colspan="1">N.R</td>
<td align="left" rowspan="1" colspan="1">1. BSS score 2. Global IBS symptom improvement</td>
<td align="left" rowspan="1" colspan="1">IBS health-related QoL score</td>
<td align="left" rowspan="1" colspan="1">28 vs. 30</td>
<td align="left" rowspan="1" colspan="1">Chang An Yi Hao decoction</td>
<td align="left" rowspan="1" colspan="1">150 ml, t.i.d.</td>
<td align="left" rowspan="1" colspan="1">8 weeks</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cai et al. 2013 (19)</td>
<td align="left" rowspan="1" colspan="1">RomeIII</td>
<td align="left" rowspan="1" colspan="1">Single center</td>
<td align="left" rowspan="1" colspan="1">stagnation of liver energy and deficiency of spleen</td>
<td align="left" rowspan="1" colspan="1">BSS score</td>
<td align="left" rowspan="1" colspan="1">Syndrome of TCM score</td>
<td align="left" rowspan="1" colspan="1">18 vs. 19</td>
<td align="left" rowspan="1" colspan="1">Shu Gan Jian Pi Wen Shen decoction</td>
<td align="left" rowspan="1" colspan="1">150 ml, t.i.d.</td>
<td align="left" rowspan="1" colspan="1">8 weeks</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Li et al. 2014 (20)</td>
<td align="left" rowspan="1" colspan="1">RomeIII</td>
<td align="left" rowspan="1" colspan="1">Single center</td>
<td align="left" rowspan="1" colspan="1">N.R</td>
<td align="left" rowspan="1" colspan="1">Global symptom improvement</td>
<td align="left" rowspan="1" colspan="1">1. Symptom improvement of mild IBS-D 2. Symptom improvement of moderate IBS-D 3. Symptom improvement of serious IBS-D</td>
<td align="left" rowspan="1" colspan="1">80 vs. 80</td>
<td align="left" rowspan="1" colspan="1">Chang Ji Tai granule</td>
<td align="left" rowspan="1" colspan="1">One package, b.i.d.</td>
<td align="left" rowspan="1" colspan="1">4 weeks</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>TCM, traditional Chinese medicine; BSS, symptom severity scale; QOL, quality of life questionnaire; N.R., not reported. The total number of patients included in this meta-analysis was 954 (SJZT vs placebo was 588 vs 366).</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0122397.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122397.t002</object-id>
<label>Table 2</label> <caption><title>The ingredients of each formula.</title></caption>
<alternatives>
<graphic id="pone.0122397.t002g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122397.t002" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">SJZT</th>
<th colspan="5" align="center" rowspan="1">Ingredients of each formula</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="4" align="left" colspan="1">Bensoussan’s formula</td>
<td align="left" rowspan="1" colspan="1"><italic>Codonopsis pilosulab</italic> (Dang shen)</td>
<td align="left" rowspan="1" colspan="1"><italic>Herba agastaches</italic> (Huo xiang)</td>
<td align="left" rowspan="1" colspan="1"><italic>Saposhnikovia divaricata</italic> (Fang feng)</td>
<td align="left" rowspan="1" colspan="1"><italic>Semen coicis</italic> (Yi yi ren)</td>
<td align="left" rowspan="1" colspan="1"><italic>Bupleuri chinensis</italic> (Chai hu)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>Herba artemisiae capillaris</italic> (Yin chen)</td>
<td align="left" rowspan="1" colspan="1"><italic>Magnoliae officinalis</italic> (Hou pu)</td>
<td align="left" rowspan="1" colspan="1"><italic>Atractylodes macrocephala</italic> (Bai zhu)</td>
<td align="left" rowspan="1" colspan="1"><italic>Citri reticulatae</italic> (Chen pi)</td>
<td align="left" rowspan="1" colspan="1"><italic>Zingiberis preparata</italic> (Pao jiang)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>Citri reticulatae immaturus</italic> (Qin pi)</td>
<td align="left" rowspan="1" colspan="1"><italic>Angelica dahurica</italic> (Bai zhi)</td>
<td align="left" rowspan="1" colspan="1"><italic>Phellodendri amurensis</italic> (Huang bai)</td>
<td align="left" rowspan="1" colspan="1"><italic>Poria cocos</italic> (Fu ling)</td>
<td align="left" rowspan="1" colspan="1"><italic>Plantaginis</italic> (Che qian zi)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>Paeoniae alba</italic> (Bai shao)</td>
<td align="left" rowspan="1" colspan="1"><italic>Aucklandiae</italic> (Mu xiang)</td>
<td align="left" rowspan="1" colspan="1"><italic>Glycyrrhizae preparata</italic> (Zhi gan cao)</td>
<td align="left" rowspan="1" colspan="1"><italic>Coptidis</italic> (Huang lian)</td>
<td align="left" rowspan="1" colspan="1"><italic>Schisandrae</italic> (Wu wei zi)</td>
</tr>
<tr>
<td rowspan="3" align="left" colspan="1">Leung’s formula</td>
<td align="left" rowspan="1" colspan="1"><italic>Astragalus membranaceus</italic> (Huang qi)</td>
<td align="left" rowspan="1" colspan="1"><italic>Paeoniae alba</italic> (Bai shao)</td>
<td align="left" rowspan="1" colspan="1"><italic>Atractylodes macrocephala</italic> (Bai zhu)</td>
<td align="left" rowspan="1" colspan="1"><italic>Bupleuri chinensis</italic> (Chai hu)</td>
<td align="left" rowspan="1" colspan="1"><italic>Atractylodes chinensis</italic> (Cang zhu)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>Citri reticulatae</italic> (Chen pi)</td>
<td align="left" rowspan="1" colspan="1"><italic>Murraya paniculata</italic> (Jiu li xiang)</td>
<td align="left" rowspan="1" colspan="1"><italic>Saposhnikovia divaricata</italic> (Fang feng)</td>
<td align="left" rowspan="1" colspan="1"><italic>Punica grantum</italic> (Shi liu pi)</td>
<td align="left" rowspan="1" colspan="1"><italic>Portulaca oleracea</italic> (Ma chi xian)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>Coptidis</italic> (Huang lian)</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td rowspan="2" align="left" colspan="1">Li’s formula</td>
<td align="left" rowspan="1" colspan="1"><italic>Paeoniae alba</italic> (Bai shao)</td>
<td align="left" rowspan="1" colspan="1"><italic>Glycyrrhizae preparata</italic> (Zhi gan cao)</td>
<td align="left" rowspan="1" colspan="1"><italic>Atractylodes macrocephala</italic> (Bai zhu)</td>
<td align="left" rowspan="1" colspan="1"><italic>Citri reticulatae</italic> (Chen pi)</td>
<td align="left" rowspan="1" colspan="1"><italic>Saposhnikovia divaricata</italic> (Fang feng)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>Fructus mume</italic> (Wu mei)</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Chen’s formula</td>
<td align="left" rowspan="1" colspan="1"><italic>Paeoniae alba</italic> (Bai shao)</td>
<td align="left" rowspan="1" colspan="1"><italic>Citri reticulatae immaturus</italic> (Qin pi)</td>
<td align="left" rowspan="1" colspan="1"><italic>Atractylodes macrocephala</italic> (Bai zhu)</td>
<td align="left" rowspan="1" colspan="1"><italic>Allii macrostemonis</italic> (Xie bai)</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td rowspan="2" align="left" colspan="1">Tang ‘s formula</td>
<td align="left" rowspan="1" colspan="1"><italic>Astragalus membranaceus</italic> (Huang qi)</td>
<td align="left" rowspan="1" colspan="1"><italic>Paeoniae alba</italic> (Bai shao)</td>
<td align="left" rowspan="1" colspan="1"><italic>Atractylodes macrocephala</italic> (Bai zhu)</td>
<td align="left" rowspan="1" colspan="1"><italic>Citri reticulatae</italic> (Chen pi)</td>
<td align="left" rowspan="1" colspan="1"><italic>Coptidis</italic> (Huang lian)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>Zingiberis preparata</italic> (Pao jiang)</td>
<td align="left" rowspan="1" colspan="1"><italic>Aucklandiae</italic> (Mu xiang)</td>
<td align="left" rowspan="1" colspan="1"><italic>Saposhnikovia divaricata</italic> (Fang feng)</td>
<td align="left" rowspan="1" colspan="1"><italic>Myristicae</italic> (Rou dou kou)</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td rowspan="3" align="left" colspan="1">Cai’s formula</td>
<td align="left" rowspan="1" colspan="1"><italic>Codonopsis pilosulab</italic> (Dang shen)</td>
<td align="left" rowspan="1" colspan="1"><italic>Paeoniae alba</italic> (Bai shao)</td>
<td align="left" rowspan="1" colspan="1"><italic>Atractylodes macrocephala</italic> (Bai zhu)</td>
<td align="left" rowspan="1" colspan="1"><italic>Poria cocos</italic> (Fu ling)</td>
<td align="left" rowspan="1" colspan="1"><italic>Curcumae wenyujin</italic> (Yu jin)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>Glycyrrhizae preparata</italic> (Zhi gan cao)</td>
<td align="left" rowspan="1" colspan="1"><italic>Alpiniae katsumadai</italic> (Cao dou kou)</td>
<td align="left" rowspan="1" colspan="1"><italic>Saposhnikovia divaricata</italic> (Fang feng)</td>
<td align="left" rowspan="1" colspan="1"><italic>Lablab album</italic> (Bai bian dou)</td>
<td align="left" rowspan="1" colspan="1"><italic>Citri reticulatae</italic> (Chen pi)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>Amomum villosum</italic> (Sha ren)</td>
<td align="left" rowspan="1" colspan="1"><italic>Albiziae</italic> (He huan pi)</td>
<td align="left" rowspan="1" colspan="1"><italic>Platycodon grandiflorum</italic> (Jie geng)</td>
<td align="left" rowspan="1" colspan="1"><italic>Semen coicis</italic> (Yi yi ren)</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>The risk of bias assessment in the trials was summarized in <xref rid="pone.0122397.g002" ref-type="fig">Fig 2</xref>. A low risk of bias was found across studies for adequate sequence generation, allocation concealment, blinding of outcome assessment and selective outcome reporting. There were no details about placebo content in Tang et al. study [<xref rid="pone.0122397.ref018" ref-type="bibr">18</xref>]. Bensoussan et al.[<xref rid="pone.0122397.ref015" ref-type="bibr">15</xref>] and Cai et al.[<xref rid="pone.0122397.ref019" ref-type="bibr">19</xref>] studies were rated as high risk for the “incomplete outcome data” item ascribing to lack of intention-to-treat (ITT) analysis.</p>
<fig id="pone.0122397.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122397.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Risk of bias assessment.</title>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122397.g002" position="float" xlink:type="simple"/>
</fig>
<sec id="sec012">
<title>Primary outcome: global symptom improvement</title>
<p>Among the included studies, six evaluated global symptom improvement [<xref rid="pone.0122397.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0122397.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0122397.ref016" ref-type="bibr">16</xref>–<xref rid="pone.0122397.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0122397.ref020" ref-type="bibr">20</xref>]: of 917 patients, 570 were assigned to the treatment groups, whereas 347 were assigned to the placebo groups. The number of participants included in this meta-analysis was slightly larger than the calculated OIS (917 vs. 794 patients). SJZT showed significant improvement in global symptoms compared to placebo (RR 1.61; 95% CI 1.24, 2.10; <italic>P</italic> = 0.0004) (<xref rid="pone.0122397.g003" ref-type="fig">Fig 3a</xref>). 76.8% of SJZT patients had global improvement over 43.8% of placebo patients (therapeutic gain = 33.0% with NNT = 3.0) (<xref rid="pone.0122397.t003" ref-type="table">Table 3</xref>). The heterogeneity was significant (<italic>P</italic> = 0.005, <italic>I</italic><sup><italic>2</italic></sup> = 70.0%). We performed a sensitivity analysis to investigate potential sources of heterogeneity and found that the Leung et al. study may be the main origin of heterogeneity in the meta-analysis [<xref rid="pone.0122397.ref012" ref-type="bibr">12</xref>]. The heterogeneity was small after exclusion of the Leung et al. study (<italic>P</italic> = 0.25, <italic>I</italic><sup><italic>2</italic></sup> = 26%). However, the corresponding pooled RR was not conspicuously altered without the Leung et al. study (RR 1.79 95% CI 1.51, 2.12) (<xref rid="pone.0122397.g003" ref-type="fig">Fig 3b</xref>). The findings supported the robustness of the analysis. No evidence of asymmetry was identified by funnel plot analysis (Begg’s test <italic>P</italic> = 0.707) (<xref rid="pone.0122397.g004" ref-type="fig">Fig 4</xref>).</p>
<fig id="pone.0122397.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122397.g003</object-id>
<label>Fig 3</label>
<caption>
<p>(a) Forest plot of primary outcomes, global symptom improvement with weights from random effects analysis. (b) Sensitivity analysis was performed by omitting one study.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122397.g003" position="float" xlink:type="simple"/>
</fig>
<fig id="pone.0122397.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122397.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Funnel plot analysis of global symptom improvement (Begg’s test, <italic>P</italic> = 0.707).</title>
<p>RR, relative risk.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122397.g004" position="float" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0122397.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122397.t003</object-id>
<label>Table 3</label> <caption><title>Global symptom improvement, SJZT vs. placebo.</title></caption>
<alternatives>
<graphic id="pone.0122397.t003g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122397.t003" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th rowspan="2" align="left" colspan="1">Study</th>
<th colspan="2" align="center" rowspan="1">Response rate, % (response/<italic>N</italic>)</th>
<th rowspan="2" align="left" colspan="1">Therapeutic gain, %</th>
<th rowspan="2" align="left" colspan="1">NNT</th>
<th rowspan="2" align="left" colspan="1">RR (95% CI)</th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1">SJZT</th>
<th align="left" rowspan="1" colspan="1">Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Bensoussan et al,1998</td>
<td align="left" rowspan="1" colspan="1">67.4 (29/43)</td>
<td align="left" rowspan="1" colspan="1">31.4 (11/35)</td>
<td align="char" char="." rowspan="1" colspan="1">36.0</td>
<td align="char" char="." rowspan="1" colspan="1">2.8</td>
<td align="left" rowspan="1" colspan="1">2.15 (1.26, 3.65)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Leung et al,2006</td>
<td align="left" rowspan="1" colspan="1">35.0 (21/60)</td>
<td align="left" rowspan="1" colspan="1">44.1 (26/59)</td>
<td align="char" char="." rowspan="1" colspan="1">-9.1</td>
<td align="left" rowspan="1" colspan="1">__</td>
<td align="left" rowspan="1" colspan="1">0.79 (0.51, 1.24)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Li et al,2010</td>
<td align="left" rowspan="1" colspan="1">83.3 (25/30)</td>
<td align="left" rowspan="1" colspan="1">60.0 (18/30)</td>
<td align="char" char="." rowspan="1" colspan="1">23.3</td>
<td align="char" char="." rowspan="1" colspan="1">4.3</td>
<td align="left" rowspan="1" colspan="1">1.39 (1.00, 1.94)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Chen et al,2010</td>
<td align="left" rowspan="1" colspan="1">85.1 (280/329)</td>
<td align="left" rowspan="1" colspan="1">44.2 (50/113)</td>
<td align="char" char="." rowspan="1" colspan="1">40.9</td>
<td align="char" char="." rowspan="1" colspan="1">2.4</td>
<td align="left" rowspan="1" colspan="1">1.92 (1.56, 2.38)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Tang et al,2011</td>
<td align="left" rowspan="1" colspan="1">89.3 (25/28)</td>
<td align="left" rowspan="1" colspan="1">36.7 (11/30)</td>
<td align="char" char="." rowspan="1" colspan="1">52.6</td>
<td align="char" char="." rowspan="1" colspan="1">1.9</td>
<td align="left" rowspan="1" colspan="1">2.44 (1.50, 3.96)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Li et al,2014</td>
<td align="left" rowspan="1" colspan="1">72.5 (58/80)</td>
<td align="left" rowspan="1" colspan="1">45.0 (36/80)</td>
<td align="char" char="." rowspan="1" colspan="1">27.5</td>
<td align="char" char="." rowspan="1" colspan="1">3.6</td>
<td align="left" rowspan="1" colspan="1">1.61 (1.22,2.13)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Pooled OR</td>
<td align="left" rowspan="1" colspan="1">76.8 (438/570)</td>
<td align="left" rowspan="1" colspan="1">43.8 (152/347)</td>
<td align="char" char="." rowspan="1" colspan="1">33.0</td>
<td align="char" char="." rowspan="1" colspan="1">3.0</td>
<td align="left" rowspan="1" colspan="1">1.61 (1.24, 2.10)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>IBS, irritable bowel syndrome; NNT, number needed to treat; RR, relative risk.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec013">
<title>Secondary outcomes</title>
<sec id="sec014">
<title>Overall BSS score</title>
<p>Four of seven studies used BSS to assess the severity of IBS symptoms [<xref rid="pone.0122397.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0122397.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0122397.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0122397.ref019" ref-type="bibr">19</xref>]. SJZT reduced the overall BSS score compared with placebo (SMD—0.67; 95% CI—0.94, –0.40; <italic>P</italic>&lt;0.00001) (<xref rid="pone.0122397.g005" ref-type="fig">Fig 5a</xref>). No substantial heterogeneity was found (<italic>P</italic> = 0.39, <italic>I</italic><sup>2</sup> = 0.0%). Funnel plot analysis demonstrated no evidence of publication bias (Begg’s test, <italic>P</italic> = 1.000) (<xref rid="pone.0122397.g006" ref-type="fig">Fig 6</xref>).</p>
<fig id="pone.0122397.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122397.g005</object-id>
<label>Fig 5</label>
<caption>
<p>(a) Forest plot of secondary outcomes, overall BSS score with weights from fixed effects analysis. (b) Forest plot of secondary outcomes, abdominal pain improvement with weights from fixed effects analysis.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122397.g005" position="float" xlink:type="simple"/>
</fig>
<fig id="pone.0122397.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122397.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Funnel plot analysis of overall BSS score (Begg’s test, <italic>P</italic> = 1.000).</title>
<p>RR, relative risk.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122397.g006" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec015">
<title>Abdominal pain improvement</title>
<p>Two of the seven studies reported the outcome of abdominal pain improvement [<xref rid="pone.0122397.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0122397.ref017" ref-type="bibr">17</xref>]. SJZT showed significant improvement for abdominal pain compared to placebo (RR 4.34; 95% CI 2.64, 7.14; <italic>P</italic>&lt;0.00001) (<xref rid="pone.0122397.g005" ref-type="fig">Fig 5b</xref>). No observed heterogeneity existed (<italic>P</italic> = 0.82, <italic>I</italic><sup>2</sup> = 0.0%).</p>
<p>Two included studies reported daily bowel frequency [<xref rid="pone.0122397.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0122397.ref016" ref-type="bibr">16</xref>], but the data could not be incorporated because Li et al.[<xref rid="pone.0122397.ref016" ref-type="bibr">16</xref>] reported daily bowel frequency with means and SD values, while Leung et al.[<xref rid="pone.0122397.ref012" ref-type="bibr">12</xref>] reported the outcome as medians.</p>
<p>Two trials assessed health-related quality of life—one used the validated Hong Kong Chinese version of the short form 36 (SF-36) [<xref rid="pone.0122397.ref012" ref-type="bibr">12</xref>], while the other used the irritable bowel syndrome quality of life questionnaire (IBS-QOL) [<xref rid="pone.0122397.ref018" ref-type="bibr">18</xref>]. Both studies reported no significant difference in health-related quality of life between the SJZT group and the placebo group. Because of the heterogeneity of instruments, meta-analysis of the quality of life score could not be conducted.</p>
</sec>
</sec>
<sec id="sec016">
<title>Safety profile and adverse events</title>
<p>Safety profile was evaluated in all the included studies. Four of these reported no adverse effects during SJZT treatment [<xref rid="pone.0122397.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0122397.ref018" ref-type="bibr">18</xref>–<xref rid="pone.0122397.ref020" ref-type="bibr">20</xref>]. Bensoussan et al. reported that two patients in the standard formula group withdrew from the study associated with gastrointestinal discomfort [<xref rid="pone.0122397.ref015" ref-type="bibr">15</xref>]. In Leung et al.’s study, two participants suffered from skin rash and thyroiditis respectively in the treatment group and one participant suffered from facial nerve palsy in the placebo group [<xref rid="pone.0122397.ref012" ref-type="bibr">12</xref>]. Chen et al. reported two cases each of mild nausea and mild pruritus [<xref rid="pone.0122397.ref017" ref-type="bibr">17</xref>]. The adverse events of SJZT were no different from those of placebo.</p>
</sec>
</sec>
<sec id="sec017" sec-type="conclusions">
<title>Discussion</title>
<p>The results from this meta-analysis revealed that SJZT showed significant improvement in global IBS symptoms (RR = 1.61), BSS score (SMD = –0.67), and abdominal pain (RR = 4.34) compared with placebo. No evidence of publication bias was found. Furthermore, the number of patients reporting adverse events of SJZT was similar to that of placebo.</p>
<p>A high placebo response rate exists in IBS patients. A series of meta-analyses showed that the proportion of placebo participants reporting global improvement was almost 40% [<xref rid="pone.0122397.ref027" ref-type="bibr">27</xref>–<xref rid="pone.0122397.ref029" ref-type="bibr">29</xref>], similar to the response effect of placebo in this meta-analysis (43.8%). The clinical benefit of SJZT for global IBS symptoms was significant, with therapeutic gains over placebo of 33.0% and NNT = 3.0. The reported NNT offered by 5-HT3 receptor antagonist was eight [<xref rid="pone.0122397.ref030" ref-type="bibr">30</xref>]. That being said, SJZT seems to be superior to 5-HT3 receptor antagonist for IBS-D. However, randomized, double-blind trials evaluating SJZT compared with 5-HT3 receptor antagonist for IBS-D have not been found in our search.</p>
<p>The pathogenesis of IBS has not been fully clarified. Numerous mechanisms involve in the development of IBS, including inflammation, gut mucosal immunology, disturbed gastrointestinal motility, gut microbes, visceral hypersensitivity, altered serotonin metabolism, and psychosocial distress [<xref rid="pone.0122397.ref031" ref-type="bibr">31</xref>–<xref rid="pone.0122397.ref036" ref-type="bibr">36</xref>]. Evidence for the effectiveness of SJZT for IBS-D was identified in modern pharmacological studies. Experimental data have demonstrated that <italic>Chang ji tai</italic> granule can relieve diarrhea symptoms, ameliorate the stress state, inhibit bowel motility, and reduce visceral hypersensitivity in rats with IBS-D, possibly by modulating the expression of substance P mRNA in the hypothalamus and colon [<xref rid="pone.0122397.ref037" ref-type="bibr">37</xref>,<xref rid="pone.0122397.ref038" ref-type="bibr">38</xref>]. <italic>Chang an yi hao</italic> decoction can significantly reduce visceral hypersensitivity and enhance anti-inflammatory activities by decreasing the expression of 5-HT and regulating the levels of anti-inflammatory cytokines in rats with IBS-D [<xref rid="pone.0122397.ref039" ref-type="bibr">39</xref>]. Further studies in vitro and in vivo of herbal formulae need to be conducted to better understand the drug mechanism</p>
<p>There was significant heterogeneity for the primary outcome. We performed a sensitivity analysis and found that the Leung et al. study may be the main origin of heterogeneity [<xref rid="pone.0122397.ref012" ref-type="bibr">12</xref>]. After exclusion of the Leung et al. study, the heterogeneity was effectively decreased while the corresponding pooled RR was not substantially altered. We checked all of the included studies carefully and found that there was difference of selection criteria of patients between Leung et al. study and the other selected studies. In Leung et al. study, diagnosis of IBS was based on Rome II criteria and the diarrhea-predominant type was defined by the author if diarrhea was present for at least 75% of the time during which a patient’s IBS was active [<xref rid="pone.0122397.ref012" ref-type="bibr">12</xref>]. The rigorous inclusion criterion of patients in Leung et al. study may contribute to the heterogeneity. Furthermore, we explored the pattern of herbal formula in Leung et al. study and found that Leung et al. added several herbs with heat-clearing functions based on SJZT, which maybe another important source of heterogeneity. Treatment based on syndrome differentiation is a characteristic of TCM. Of the included seven studies, the information for TCM syndrome classification was taken into consideration only in four studies [<xref rid="pone.0122397.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0122397.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0122397.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0122397.ref019" ref-type="bibr">19</xref>]. For this reason, syndrome classification could be a matter of heterogeneity among the evaluated trials.</p>
<p>The methodological quality of included studies was general high. However, we did identified potential bias in two domains. Details about the chemical properties of placebo were not reported in Tang et al. study [<xref rid="pone.0122397.ref018" ref-type="bibr">18</xref>]. The extremely high response (89.3%) in the SJZT group in Tang et al. study may be related to spontaneous unblinding that the patient is aware of which treatment he or she is taking. The other flaw in the quality of included studies was the lack of ITT analysis, which could lead to incomplete outcome data. A total of 8 patients withdrew from the Bensoussan et al. study [<xref rid="pone.0122397.ref015" ref-type="bibr">15</xref>], of whom three patients were related to ineffective intervention. Cai et al. excluded two patients because of ineffective intervention [<xref rid="pone.0122397.ref019" ref-type="bibr">19</xref>]. Neither of these studies used ITT analysis and both of the studies were graded as high risk in incomplete outcome data. However, we extracted data as ITT analyses, assuming all drop-outs to be treatment failures, which could reduce the risk of attrition bias.</p>
<p>This meta-analysis had several limitations. First, the absolute number of clinical trials and the sample size of included studies were small. It needed to be demonstrated whether the effect size of SJZT would remain the same when applied in future large-scale trials. In the assessment of publication bias, the power of this meta- analysis was modest due to the small number of trials. Thus, there might be the possible existence of publication bias in our analysis. Second, in the included studies, patients in SJZT group were treated for 3 to 16 weeks under controlled conditions. The treatment duration was not long enough to evaluate the long term safety of SJZT for IBS-D. Third, only three of the included seven trials described follow-up evaluation [<xref rid="pone.0122397.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0122397.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0122397.ref016" ref-type="bibr">16</xref>]. Bensoussan et al. reported that, on follow-up 14 weeks after intervention completed, only the individualized formula treatment group maintained improvement rather than the standard formula group [<xref rid="pone.0122397.ref015" ref-type="bibr">15</xref>]. Because of the recurrent and chronic nature of IBS, long-term follow-up trials might yield different results. Therefore, it is necessary to specify the duration of the follow-up period with SJZT treatment. Fourth, discrepancy in formula composition, methods of preparation, and dose was observed between the studies, which may result heterogeneous.</p>
<p>In summary, the meta-analysis suggests that SJZT is more efficacious than placebo in improving global symptoms, BSS score, and abdominal pain for patients with IBS-D. SJZT is safe in short-term trials. However, due to the high clinical heterogeneity and small sample size of the included trials, further standardized preparation, randomized double-blind, multicenter, large-scale trials are required.</p>
</sec>
<sec id="sec018">
<title>Supporting Information</title>
<supplementary-material id="pone.0122397.s001" xlink:href="info:doi/10.1371/journal.pone.0122397.s001" mimetype="application/msword" position="float" xlink:type="simple">
<label>S1 PRISMA Checklist</label>
<caption>
<p>(DOC)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0122397.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saito</surname> <given-names>YA</given-names></name>, <name name-style="western"><surname>Schoenfeld</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Locke</surname> <given-names>GR</given-names> <suffix>3rd</suffix></name> (<year>2002</year>) <article-title>The epidemiology of irritable bowel syndrome in North America: a systematic review</article-title>. <source>Am J Gastroenterol</source> <volume>97</volume>: <fpage>1910</fpage>–<lpage>1915</lpage>. <object-id pub-id-type="pmid">12190153</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lovell</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Ford</surname> <given-names>AC</given-names></name> (<year>2012</year>) <article-title>Global prevalence of, and risk factors for, irritable bowel syndrome: a meta-analysis</article-title>. <source>Clin Gastroenterol Hepatol</source> <volume>10</volume>: <fpage>712</fpage>–<lpage>721</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cgh.2012.02.029" xlink:type="simple">10.1016/j.cgh.2012.02.029</ext-link></comment> <object-id pub-id-type="pmid">22426087</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grundmann</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Yoon</surname> <given-names>SL</given-names></name> (<year>2010</year>) <article-title>Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners</article-title>. <source>J Gastroenterol Hepatol</source> <volume>25</volume>: <fpage>691</fpage>–<lpage>699</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1440-1746.2009.06120.x" xlink:type="simple">10.1111/j.1440-1746.2009.06120.x</ext-link></comment> <object-id pub-id-type="pmid">20074154</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>El-Serag</surname> <given-names>HB</given-names></name>, <name name-style="western"><surname>Olden</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Bjorkman</surname> <given-names>D</given-names></name> (<year>2002</year>) <article-title>Health-related quality of life among persons with irritable bowel syndrome: a systematic review</article-title>. <source>Aliment Pharmacol Ther</source> <volume>16</volume>: <fpage>1171</fpage>–<lpage>1185</lpage>. <object-id pub-id-type="pmid">12030961</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dean</surname> <given-names>BB</given-names></name>, <name name-style="western"><surname>Aguilar</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Barghout</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Kahler</surname> <given-names>KH</given-names></name>, <name name-style="western"><surname>Frech</surname> <given-names>F</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Impairment in work productivity and health-related quality of life in patients with IBS</article-title>. <source>Am J Manag Care</source> <volume>11</volume>(<issue>Suppl 1</issue>): <fpage>S17</fpage>–<lpage>26</lpage>.</mixed-citation></ref>
<ref id="pone.0122397.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Talley</surname> <given-names>NJ</given-names></name>, <name name-style="western"><surname>Gabriel</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Harmsen</surname> <given-names>WS</given-names></name>, <name name-style="western"><surname>Zinsmeister</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Evans</surname> <given-names>RW</given-names></name> (<year>1995</year>) <article-title>Medical costs in community subjects with irritable bowel syndrome</article-title>. <source>Gastroenterology</source> <volume>109</volume>: <fpage>1736</fpage>–<lpage>1741</lpage>. <object-id pub-id-type="pmid">7498636</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brandt</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Chey</surname> <given-names>WD</given-names></name>, <name name-style="western"><surname>Foxx-Orenstein</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Schiller</surname> <given-names>LR</given-names></name>, <name name-style="western"><surname>Schoenfeld</surname> <given-names>PS</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>An evidence-based position statement on the management of irritable bowel syndrome</article-title>. <source>Am J Gastroenterol</source> <volume>104</volume>(<issue>Suppl 1</issue>): <fpage>S1</fpage>–<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ajg.2008.122" xlink:type="simple">10.1038/ajg.2008.122</ext-link></comment> <object-id pub-id-type="pmid">19521341</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hussain</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Quigley</surname> <given-names>EM</given-names></name> (<year>2006</year>) <article-title>Systematic review: complementary and alternative medicine in the irritable bowel syndrome</article-title>. <source>Aliment Pharmacol Ther</source> <volume>23</volume>: <fpage>465</fpage>–<lpage>471</lpage>. <object-id pub-id-type="pmid">16441466</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>YX</given-names></name>, <name name-style="western"><surname>Wei</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Grimsgaard</surname> <given-names>S</given-names></name> (<year>2006</year>) <article-title>Herbal medicines for treatment of irritable bowel syndrome</article-title>. <source>Cochrane Database Syst Rev</source> <volume>25</volume>: <fpage>CD004116</fpage>. <object-id pub-id-type="pmid">16437473</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shi</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Tong</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Shen</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>HX</given-names></name> (<year>2008</year>) <article-title>Effectiveness and safety of herb medicines in the treatment of irritable bowel syndrome: a systematic review</article-title>. <source>World J Gastroenterol</source> <volume>14</volume>: <fpage>454</fpage>–<lpage>462</lpage>. <object-id pub-id-type="pmid">18200670</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">Chinese Society of Digestive Diseases and Chinese Association of Chinese Medicine</collab> (<year>2010</year>) <article-title>Consensus on the diagnosis and treatment of functional dyspepsia irritable bowel syndrome by Traditional Chinese Medicine</article-title>. <source>China J Trad Chin Med Pharm</source> <volume>25</volume>:<fpage>1062</fpage>–<lpage>1065</lpage>.</mixed-citation></ref>
<ref id="pone.0122397.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leung</surname> <given-names>WK</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Liang</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>LS</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>FK</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo controlled trial</article-title>. <source>Am J Gastroenterol</source> <volume>101</volume>: <fpage>1574</fpage>–<lpage>1580</lpage>. <object-id pub-id-type="pmid">16863563</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sung</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>WK</given-names></name>, <name name-style="western"><surname>Ching</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Lao</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>G</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Agreements among traditional Chinese medicine practitioners in the diagnosis and treatment of irritable bowel syndrome</article-title>. <source>Aliment Pharmacol Ther</source> <volume>20</volume>: <fpage>1205</fpage>–<lpage>1210</lpage>. <object-id pub-id-type="pmid">15569124</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bian</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Miao</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wong</surname> <given-names>H</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Effectiveness of Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review</article-title>. <source>J Altern Complement Med</source> <volume>12</volume>: <fpage>401</fpage>–<lpage>407</lpage>. <object-id pub-id-type="pmid">16722791</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bensoussan</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Talley</surname> <given-names>NJ</given-names></name>, <name name-style="western"><surname>Hing</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Menzies</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Guo</surname> <given-names>A</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial</article-title>. <source>JAMA</source> <volume>280</volume>: <fpage>1585</fpage>–<lpage>1589</lpage>. <object-id pub-id-type="pmid">9820260</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>YM</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>YN</given-names></name>, <name name-style="western"><surname>Cai</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>MX</given-names></name> (<year>2010</year>) <article-title>Treatment of diarrhea-predominant irritable bowel syndrome with Chang Ji Tai Granule: A randomized, double-blinded and placebo-controlled trial</article-title>. <source>Shanghai J Trad Chin Med</source> <volume>44</volume>: <fpage>33</fpage>–<lpage>36</lpage>.</mixed-citation></ref>
<ref id="pone.0122397.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>DF</given-names></name>, <name name-style="western"><surname>Xia</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Gong</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>XL</given-names></name>, <name name-style="western"><surname>Jiang</surname> <given-names>YP</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Effects of Tong Xie Ning granule in treatment of diarrhea-predominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled, multicenter study</article-title>. <source>Chin J Dig</source> <volume>30</volume>: <fpage>327</fpage>–<lpage>330</lpage>.</mixed-citation></ref>
<ref id="pone.0122397.ref018"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Tang XD, Li ZH, Li BS, Gao R, Wang FY, et al. (2011) Treatment of diarrhea-predominant irritable bowel syndrome with Chang An Yi Hao decoction: A randomized, double-blinded and placebo-controlled trial. Seventh National Symposium of Rehabilitation Medicine Health Professional Committee, Chinese Association of Integrative Medicine 1–9.</mixed-citation></ref>
<ref id="pone.0122397.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cai</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Lv</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Meng</surname> <given-names>LN</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Fan</surname> <given-names>YH</given-names></name> (<year>2013</year>) <article-title>Treatment of diarrhea-predominant irritable bowel syndrome with Shu Gan Jian Pi Wen Shen decoction: A randomized controlled trial</article-title>. <source>Chin Arch Trad Chin Med</source> <volume>5</volume>: <fpage>1097</fpage>–<lpage>1099</lpage>.</mixed-citation></ref>
<ref id="pone.0122397.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>YM</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Cai</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>MX</given-names></name> (<year>2014</year>) <article-title>A randomized, double-blinded and placebo-controlled research on Chang Ji Tai combined with percutaneous acupoint stimulation of in treatment of diarrhea-predominant irritable bowel syndrome</article-title>. <source>Chin J Integr Trad West Med Dig</source> <volume>22</volume>: <fpage>1</fpage>–<lpage>4</lpage>.</mixed-citation></ref>
<ref id="pone.0122397.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xiao</surname> <given-names>HT</given-names></name>, <name name-style="western"><surname>Zhong</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Tsang</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>ZS</given-names></name>, <name name-style="western"><surname>Bian</surname> <given-names>ZX</given-names></name> (<year>2015</year>) <article-title>Traditional Chinese Medicine Formulas for Irritable Bowel Syndrome: From Ancent Wisdoms to Scientific Understandings</article-title>. <source>Am J Chin Med</source> <volume>11</volume>: <fpage>1</fpage>–<lpage>23</lpage>.</mixed-citation></ref>
<ref id="pone.0122397.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Deeks</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name> (<year>2003</year>) <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ</source> <volume>327</volume>: <fpage>557</fpage>–<lpage>560</lpage>. <object-id pub-id-type="pmid">12958120</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DerSimonian</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Laird</surname> <given-names>N</given-names></name> (<year>1986</year>) <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source> <volume>7</volume>:<fpage>177</fpage>–<lpage>188</lpage>. <object-id pub-id-type="pmid">3802833</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>10101</lpage>. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pogue</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Yusuf</surname> <given-names>S</given-names></name> (<year>1997</year>) <article-title>Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis</article-title>. <source>Control Clin Trials</source> <volume>18</volume>: <fpage>580</fpage>–<lpage>593</lpage>. <object-id pub-id-type="pmid">9408720</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alonso-Coello</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Martinez-Zapata</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Mills</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Heels-Ansdell</surname> <given-names>D</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Meta-analysis of flavonoids for the treatment of haemorrhoids</article-title>. <source>Br J Surg</source> <volume>93</volume>:<fpage>909</fpage>–<lpage>920</lpage>. <object-id pub-id-type="pmid">16736537</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ford</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Moayyedi</surname> <given-names>P</given-names></name> (<year>2010</year>) <article-title>Meta-analysis: factors affecting placebo response rate in irritable bowel syndrome</article-title>. <source>Aliment Pharmacol Ther</source> <volume>32</volume>: <fpage>144</fpage>–<lpage>158</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2036.2010.04328.x" xlink:type="simple">10.1111/j.1365-2036.2010.04328.x</ext-link></comment> <object-id pub-id-type="pmid">20412064</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dorn</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>Kaptchuk</surname> <given-names>TJ</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Nguyen</surname> <given-names>LT</given-names></name>, <name name-style="western"><surname>Canenguez</surname> <given-names>K</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome</article-title>. <source>Neurogastroenterol Motil</source> <volume>19</volume>: <fpage>630</fpage>–<lpage>637</lpage>. <object-id pub-id-type="pmid">17640177</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sands</surname> <given-names>BE</given-names></name> (<year>2009</year>) <article-title>The placebo response rate in irritable bowel syndrome and inflammatory bowel disease</article-title>. <source>Dig Dis</source> <volume>27</volume>(<issue>Suppl 1</issue>): <fpage>68</fpage>–<lpage>75</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000268123" xlink:type="simple">10.1159/000268123</ext-link></comment> <object-id pub-id-type="pmid">20203499</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ford</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Brandt</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Young</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Chey</surname> <given-names>WD</given-names></name>, <name name-style="western"><surname>Foxx-Orenstein</surname> <given-names>AE</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis</article-title>. <source>Am J Gastroenterol</source> <volume>104</volume>: <fpage>1831</fpage>–<lpage>1843</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ajg.2009.223" xlink:type="simple">10.1038/ajg.2009.223</ext-link></comment> <object-id pub-id-type="pmid">19471254</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chang</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Talley</surname> <given-names>NJ</given-names></name> (<year>2010</year>) <article-title>Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment</article-title>. <source>Trends Pharmacol Sci</source> <volume>31</volume>: <fpage>326</fpage>–<lpage>334</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.tips.2010.04.008" xlink:type="simple">10.1016/j.tips.2010.04.008</ext-link></comment> <object-id pub-id-type="pmid">20554042</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rapps</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>van Oudenhove</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Enck</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Aziz</surname> <given-names>Q</given-names></name> (<year>2008</year>) <article-title>Brain imaging of visceral functions in healthy volunteers and IBS patients</article-title>. <source>J Psychosom Res</source> <volume>64</volume>: <fpage>599</fpage>–<lpage>604</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jpsychores.2008.02.018" xlink:type="simple">10.1016/j.jpsychores.2008.02.018</ext-link></comment> <object-id pub-id-type="pmid">18501260</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ringel</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Maharshak</surname> <given-names>N</given-names></name> (<year>2013</year>) <article-title>Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source> <volume>305</volume>: <fpage>G529</fpage>–<lpage>541</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1152/ajpgi.00207.2012" xlink:type="simple">10.1152/ajpgi.00207.2012</ext-link></comment> <object-id pub-id-type="pmid">23886861</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Törnblom</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Lindberg</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Nyberg</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Veress</surname> <given-names>B</given-names></name> (<year>2002</year>) <article-title>Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome</article-title>. <source>Gastroenterology</source> <volume>123</volume>: <fpage>1972</fpage>–<lpage>1979</lpage>. <object-id pub-id-type="pmid">12454854</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Karantanos</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Markoutsaki</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Gazouli</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Anagnou</surname> <given-names>NP</given-names></name>, <name name-style="western"><surname>Karamanolis</surname> <given-names>DG</given-names></name> (<year>2010</year>) <article-title>Current insights in to the pathophysiology of irritable bowel syndrome</article-title>. <source>Gut Pathog</source> <volume>2</volume>: <fpage>3</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1757-4749-2-3" xlink:type="simple">10.1186/1757-4749-2-3</ext-link></comment> <object-id pub-id-type="pmid">20465787</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chitkara</surname> <given-names>DK</given-names></name>, <name name-style="western"><surname>van Tilburg</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Blois-Martin</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Whitehead</surname> <given-names>WE</given-names></name> (<year>2008</year>) <article-title>Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review</article-title>. <source>Am J Gastroenterol</source> <volume>103</volume>: <fpage>765</fpage>–<lpage>774</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1572-0241.2007.01722.x" xlink:type="simple">10.1111/j.1572-0241.2007.01722.x</ext-link></comment> <object-id pub-id-type="pmid">18177446</object-id></mixed-citation></ref>
<ref id="pone.0122397.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cong</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Cai</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>J</given-names></name>,<name name-style="western"><surname>Zhang</surname> <given-names>ZL</given-names></name> (<year>2013</year>) <article-title>Effect of Chang Ji Tai decoction on expression of substance P mRNA in the colonic mucosa and hypothalamus of rats with diarrhea-predominant irritable bowel syndrome</article-title>. <source>World Chin J Digest</source> <volume>21</volume>: <fpage>1234</fpage>–<lpage>1238</lpage>.</mixed-citation></ref>
<ref id="pone.0122397.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>YM</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>L</given-names></name>,<name name-style="western"><surname>Cai</surname> <given-names>G</given-names></name> (<year>2010</year>) <article-title>Effect of Chang Ji Tai on voltage-gated sodium channel Nav1.8 and nerve growth factor in the rats with visceral hypersensitivity</article-title>. <source>Chin J Integr Trad West Med Dig</source><volume>18</volume>:<fpage>355</fpage>–<lpage>358</lpage>.</mixed-citation></ref>
<ref id="pone.0122397.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Tang</surname> <given-names>XD</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>FY</given-names></name>, <name name-style="western"><surname>Bian</surname> <given-names>ZX</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>JQ</given-names></name> (<year>2012</year>) <article-title>Effect of Chang An Yi Hao decoction and placebo on TNF-α and IL-10 in rats with irritable bowel syndrome of diarrhea pattern</article-title>. <source>Shanghai J TCM</source> <volume>46</volume>:<fpage>82</fpage>–<lpage>84</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>